Author:
Dhanorkar Vandana,Shah Pranav
Abstract
Abstract
Background
Currently, the Bilayer tablets, Tablet in tablet and Inlay tablets composed of Glimepiride (GMP) and Pioglitazone (PGH) as immediate release part, and Metformin (MFH) as sustained-release part are available for the treatment of type II diabetes mellitus (T2DM). In these products, there is a possibility of the incomplete release of immediate release part (GMP and PGH) due to their entrapment into high viscosity gel barrier of MFH sustained-release part when drug product comes in contact with media. Therefore, the present study was aimed to deliver the above combination drugs in the form of hard gelatin capsules (as unit dosage form) containing MFH sustained-release (MFH-SR) pellets and immediate release pellets of PGH and GMP (PG-IR).
Results
The MFH-SR and GP-IR pellets, prepared by extrusion and spheronization technique, were optimized based on the drug content and % cumulative drug release. The MFH-SR pellets formulation (batch A6) has shown maximum drug content, and sustained-release of MFH similar to marketed glucophage tablet while, the GP-IR pellets formulation (batch B5) has displayed maximum drug contents and immediate release of GMP and PGH; thus, these batches were considered for further characterizations. The optimized MFH-SR and GP-IR formulations have shown particle sizes of 0.23 ± 0.0010 mm and 0.35 ± 0.0018 mm, respectively. Besides, the formulations exhibited good micromeritics properties. The in vivo pharmacokinetic study in rabbits has demonstrated comparable bioavailability of the drugs from pellets and the marketed formulations following oral administration. Further, the pellets were found to be stable for 6 months at 40 ± 2 °C/75% ± 5%RH.
Conclusions
The study results revealed that the multiparticulate systems with varied release profiles could be a promising approach to overcome drug release issues associated with the unit dosage forms.
Publisher
Springer Science and Business Media LLC
Reference21 articles.
1. Pouya S, Inga P, Paraskevi S. Global and regional diabetes prevalence estimates for 2019 and projections for 2030 and 2045 (2019) Results from the International Diabetes Federation Diabets Atlas, Diabets Research and Clinical Practice 11:57
2. Thangavel MV, Jayasutha J, Vishnu MC, Dasari H, Yalamanchili DT, Damodharan N (2017) Safety, efficacy, and bioavailability of fixed-dose combinations in type 2 diabetes mellitus: A systematic updated review. Curr Ther Res Clin Exp 84:4–9
3. Lobovitz HE (1991) Therapy for Diabetes mellitus and related disorders: American Diabetes Association. Alexandria, pp 114–22
4. Gowthamarajan K, Kulkarni GT (2003) Oral insulin fact or fiction. Resonance 8(5):38–46
5. Lee VHL, Robinson JR (1987) Influence of drug properties and routes of drug administration on the design of sustained and controlled release system. Control Drug Deliv Fund and Applic Marcel Dekker, New York, pp 3–94
Cited by
2 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献